GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » PS Ratio

Vascular Biogenics (Vascular Biogenics) PS Ratio : 25.83 (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vascular Biogenics's share price is $0.155. Vascular Biogenics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01. Hence, Vascular Biogenics's PS Ratio for today is 25.83.

The historical rank and industry rank for Vascular Biogenics's PS Ratio or its related term are showing as below:

VBLT' s PS Ratio Range Over the Past 10 Years
Min: 1.2   Med: 65.5   Max: 261.25
Current: 25.83

During the past 11 years, Vascular Biogenics's highest PS Ratio was 261.25. The lowest was 1.20. And the median was 65.50.

VBLT's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.03 vs VBLT: 25.83

Vascular Biogenics's Revenue per Sharefor the three months ended in Jun. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.01.

Warning Sign:

Vascular Biogenics Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Vascular Biogenics was -25.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -20.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -46.20% per year.

During the past 11 years, Vascular Biogenics's highest 3-Year average Revenue per Share Growth Rate was -12.60% per year. The lowest was -65.40% per year. And the median was -20.60% per year.

Back to Basics: PS Ratio


Vascular Biogenics PS Ratio Historical Data

The historical data trend for Vascular Biogenics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics PS Ratio Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.89 75.00 90.00 164.17 15.00

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 201.25 14.12 15.00 23.93 38.33

Competitive Comparison of Vascular Biogenics's PS Ratio

For the Biotechnology subindustry, Vascular Biogenics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's PS Ratio falls into.



Vascular Biogenics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Vascular Biogenics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.155/0.006
=25.83

Vascular Biogenics's Share Price of today is $0.155.
Vascular Biogenics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Vascular Biogenics  (NAS:VBLT) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Vascular Biogenics PS Ratio Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Biogenics (Vascular Biogenics) Business Description

Traded in Other Exchanges
N/A
Address
8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Executives
Builders Vc Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim 10 percent owner C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p. 10 percent owner 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner officer: Chief Scientific Officer 320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi director 320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock director, officer: Chief Executive Officer 320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen director 320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p. 10 percent owner 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p. 10 percent owner C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p. 10 percent owner 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg director C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142